Anti-CD40 Antibody Pipeline Insight, 2018 Report - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Aug 31, 2018--The “Anti-CD40 Antibody -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
‘Anti-CD40 Antibody - Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD40 Antibody development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Descriptive coverage of pipeline development activities for Anti-CD40 Antibody - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Anti-CD40 Antibody - Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Anti-CD40 Antibody
4. Comparative Analysis
5. Anti-CD40 Antibody Pipeline Products in Clinical StagesProduct Description Research and Development Product Development Activities
6. Anti-CD40 Antibody Pipeline Products in Non-clinical StagesProduct Description Research and Development Product Development Activities
7. Therapeutic Assessment: Active ProductsPipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline ProductsProduct Description Research and Development Product Development Activities Reason for dormancy/discontinuation
Companies MentionedNovartis Boehringer Ingelheim FF Pharma Xencor Astellas Pharma
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mwr4nl/anticd40?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180831005403/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/31/2018 01:18 PM/DISC: 08/31/2018 01:18 PM